ANKH and neoplasm: Similarly, CT26 tumor–bearing animals treated with mANK-101 or systemic CTLA-4 blockade alone had 40% and 60% tumor-free survival rates respectively, while the combination had a 90% tumor-free survival rate (Supplemental Figure 7).